Biomedical subjects
W D Appler
Publications and source records attributed to W D Appler.
View from the Nation's Capital. The FDA in the 1990s.
Explore the source record for details and available documents.
FDA reconsiders ban on home kits for HIV antibody testing.
Explore the source record for details and available documents.
View from the Nation's Capital. Combating research misconduct.
Explore the source record for details and available documents.
View from the Nation's Capital. Prescription drug benefits under Medicare: potential effects on physician prescribing practices.
Explore the source record for details and available documents.
View from the Nation's Capital. "Off-label" uses of approved drugs: limits on physicians' prescribing behavior.
Explore the source record for details and available documents.
View from the Nation's Capital.
After several years of intensive debate and drafting, Congress has newly enacted legislation that will substantially change the traditional system by which drugs are distributed to physicians. While Congress acted with some specific and well-defined abuses before it, it had little empirical data that these changes would or could be effective to deal with the abuses. In the past, when Congress has enacted comprehensive legislation (changes in the Tax Code are a recent example), it has generally had to pass correcting legislation in the next session. It remains to be seen whether this Act will work without substantial corrections, particularly given the widespread disfavor it has met in the drug industry. Hopefully, it is the questionable drug practices that will be ended, rather than simply the convenient access physicians have long had both to established and newly approved drug products. An unfortunate but likely side effect of the Act is that data will be generated in the field if physicians can no longer easily receive free samples for distribution to patients without cost and for subsequent monitoring of drug safety and efficacy.
View from the Nation's Capital. DEA considers relaxing restrictions on medical use of marijuana.
Explore the source record for details and available documents.
View from the Nation's Capital. Proposed legislation would extend medical device reporting requirements to health care facilities.
Explore the source record for details and available documents.
FDA's treatment investigational new drug rule: one year later.
Explore the source record for details and available documents.
View from the Nation's Capital. FDA moves forward (and backwards) on a number of simmering issues.
Explore the source record for details and available documents.
View from the Nation's Capital. Drug abuse policy: policy or politics?
Explore the source record for details and available documents.
View from the Nation's Capital.
Explore the source record for details and available documents.
View from the Nation's Capital.
Explore the source record for details and available documents.
View from the Nation's Capital. FDA challenged successfully on its policies regarding good manufacturing practice inspections of medical drug and device manufacturers.
Explore the source record for details and available documents.
View from the Nation's Capital. NIH and ADAMHA FY 1986 appropriations.
Explore the source record for details and available documents.
View from the Nation's Capital.
Explore the source record for details and available documents.
View from the Nation's Capital. The battle over indirect costs.
Explore the source record for details and available documents.